Arovella Therapeutics Ltd (ASX: ALA), a biotechnology company focused on developing its invariant Natural Killer T (iNKT) cell platform to treat blood cancers, is pleased to announce that it has agreed the commercial terms for the initial manufacturing Services Agreement for its first investigative CAR19-iNKT cell therapy candidate (ALA-101) with Q-Gen Cell Therapeutics (Q-Gen), the cell therapy manufacturing arm of the QIMR Berghofer Medical Research Institute (QIMR Berghofer). Streamlining manufacturing is a critical step to initiate clinical trials for Arovella’s lead product, ALA-101 to treat CD19-producing leukemias and lymphomas.
In January 2022, Arovella selected the manufacturer for its clinical grade lentiviral vector and with the selection of Q-Gen, the manufacturers are now in place to generate ALA-101 for clinical trials. Arovella’s CAR19-iNKT cells are being developed to be used off-the-shelf, meaning that the therapy can be manufactured from a healthy donor, frozen and given to patients when needed, without any delay unlike the FDA approved autologous CAR-T cell therapies. Arovella expects this to make the therapy potentially more readily available, more affordable and will enable it to reach more cancer patients.
For more information, download the attached PDF.
Download this document
